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associated with high percentage of bcl-2 and Ki 67-positive tumor cells
Visok procenat bcl-2 i Ki-67 pozitivnih tumorskih ćelija udružen je sa lošijom
prognozom kod bolesnika sa difuznim krupnoćelijskim B- limfomom
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Abstract
Background/Aim. Newly diagnosed patients with diffuse
large B-cell lymphoma (DLBCL) tretaed with immunoche-
motherapy have durable remission and improved overall sur-
vival. It is important to identify high risk patients who may
benefit from even more effective therapies. Methods. In a
group of 50 newly diagnosed patients with DLBCL, treated
with CHOP/R-CHOP (cyclophosphemide doxorubicine,
vincristine, prednisone with or without rituximab) regimen,
we analyzed the prognostic value of the expression of Ki67
and bcl-2 at diagnosis as well as other standard clinical pa-
rameters: International Prognostic Index (IPI), bulky disease,
extranodal distribution and lactat dehydrogenase (LDH). Sig-
nificance was tested according to response rate and overall
survival.  Results.  Univariate survival analysis showed that
high IPI had a statistically significant negative influence on
overall and event free survival time (log rank, p < 0.01). The
log rank test analysis signified that patients with a high prolif-
erative fraction (Ki-67 > 60%) had a worse overall survival
rate (OS5y) of 40% compared to those with low proliferation
(Ki-67  <  60%) with OS5y of 80% (p < 0.01).  There  was  a
clear difference between bcl-2 positivity (treshold 50%) and
the achievement of complete remission (66% vs 86% in pa-
tients with bcl-2 high and low levels respectively, p < 0.05). In
survival analysis, patients with low bcl-2 expression had sig-
nificantly higher OS5y - 68% compared to those with high
bcl-2+ with OS5y 37% (p < 0.05). Multivariate analysis per-
formed by Cox model revealed that IPI > 3, high Ki-67+,
bcl-2 positivity had a significant independent prognostic value
concerning overall survival (p < 0.05). Conclusion. An initial
high IPI score associated with high Ki-67+ and bcl2+ could
represent possible predictive factors of poor prognosis, which
would help to identify a high risk subgroup of newly diag-
nosed DLBCL.
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Apstrakt
Uvod/Cilj. Novodijagnostikovani bolesnici sa difuznim kru-
pnoćelijskim B-limfomom (DBKL) lečeni imunohemiotera-
pijom imaju duge remisije i bolje ukupno preživljavanje. Važ-
no je otkriti bolesnike sa visokim rizikom kojima primena efi-
kasnijeg terapijskog pristupa može pomoći. Metode. U grupi
od 50 novodijagnostikovanih bolesnika sa DBKL lečenih
protokolom CHOP/R-CHOP (ciklofosfamid, doksorubicin,
vinkristin, prednizon sa ili bez rituksimaba), analizirali smo
prognostičku vrednost ekspresije Ki-67 i bcl-2 u trenutku po-
stavljanja dijagnoze, uključujući i kliničke parametre: interna-
cionalni prognozni indeks (IPI), voluminoznu tumorsku ma-
su, ekstranodalnu lokalizaciju bolesti, nivo laktat-
dehidrogenaze. Njihova značajnost testirana je u odnosu na
terapijski odgovor i ukupno preživljavanje. Rezultati. Univa-
rijantna analiza preživljavanja pokazala je da visok IPI ima
statistički značajan negativan uticaj na event-free survival i ukup-
no preživljavanje (logrank test, p < 0,01). Analiza logrank tes-
tom pokazala je da bolesnici sa DBKL koji ima visok prolife-
rativni indeks (Ki-67 > 60%) imaju lošije ukupno preživljava-
nje u odnosu na one sa niskom proliferacijom (Ki-67 < 60%)
(40% : 80%, p < 0,01). Postoji jasna razlika između bcl-2 po-
zitivnosti (granična vrednost 50%) i postizanja potpune remi-
sije (66% : 86% između bcl-2 pozitivnih i negativnih bolesni-
ka, p < 0,05). U analizi preživljavanja bcl-2 negativni bolesnici
imaju značajno bolje preživljvanje u odnosu na bcl-2 pozitiv-
ne bolesnike (68% prema 37%, p < 0,05).  Multivarijantna
analiza izvedena prema Koksovom modelu pokazala je da
IPI > 3, visoka Ki-67 i bcl-2 pozitivnost imaju značaj nezavi-
sne prognostičke varijable u pogledu ukupnog preživljavanja.
(p < 0,05). Zaključak. Visoka vrednost IPI u trenutku posta-
vljanja dijagnoze udružena sa visokim vrednostima Ki-67 i
bcl-2+ potencijalno mogu predstavljati faktore lošije progno-
ze koji mogu pomoći u otkrivanju visokorizičnih bolesnika sa
DBKL dijagnozom.
Ključne reči:
limfom, b-ćelije; geni, bcl-2; antigen, Ki-67; prognoza;
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most
common subtype of Non-Hodgkin lymphoma (NHL) ac-
counting for 30% of all newly diagnosed cases 
1, 2. The
CHOP (cyclophosphamide, doxorubicine, vincristine, pred-
nisone) regimen alone or with rituximab (CHOP/R) is stan-
dard therapeutic approach for the most patients who have
DLBCL. Even with current treatment approaches, a substan-
tial minority of patients (about 30%) are not cured 
3, 4. The
International Prognostic Index (IPI) is the most important
tool for predicting response to treatment for DLBCL 
5.  A
substantial variability in outcome has been observed despite
IPI subgroups 
6. Thus, identifying new prognostic parameters
might contribute towards better prediction of outcome and
the development of effective risk-adaptive strategies 
7.
In all clinical models, including the IPI index, there was
marked residual heterogenity in outcome, as reflected by the
considerably variable survival of patients with identical
prognostic scores 
6. The latter was attributed to the marked
genetic and molecular heterogeneity that underlies disease
aggressiveness and tumor progression, and led to the evalua-
tion of molecular and genetic markers associated with pa-
tients survival 
6. The hallmark features of the tumor cell phe-
notype, which contribute to aggressive tumor behaviour are:
its capacity for sustained proliferation, evasion of apoptosis,
disregard of signals to stop proliferation and differentiation
and the capacity to invade and promote angiogenesis 
8.
Ki-67 is a nuclear antigen expressed by dividing cells.
The percentage of Ki-67 expressing cells reflects the propor-
tion of the tumor cells that are actively cycling and divid-
ing 
6.
Bcl-2 is an anti-apoptotic protein that is important in
normal B-cell development and differentiation 
4. The role of
bcl-2 as a predictor of survival in DLBCL is controversial 
9.
Overexpression of bcl-2 protein in NHL cells has been
blamed for their resistance to chemotherapy both in vitro and
in vivo 
10–13. Bcl-2 overexpression has been reported in ap-
proximately 40-60% of patients with DLBCL and has been
associated with inferior survival 
4. Rituximab can mitigate
the negative prognostic effect of bcl-2 expression in
DLBCL 
3.
Herein, we evaluate the prognostic significance of ini-
tial bcl-2 and Ki-67 positivity in tumor cells. Furthermore we
correlate these parameters with IPI and bulky disease and
their significance was evaluated according to treatment re-
sponse and overall survival.
Methods
Retrospective analysis was performed on 50 randomly
selected patients diagnosed at the Institute of Hematology
from 2001 to 2003. Patients included in the study had an ini-
tial diagnosis of DLBCL according to the World Health Or-
ganization (WHO) classification 
14. Clinical and laboratory
data from the time of initial diagnosis as well as follow up
information were available. The follow-up period was up to
6 years, with median follow-up time for all patients of 40
months from the date of starting the treatment up to the last
follow-up or death.
The cases with histologic transformation of indolent
lymphoma into DLBCL were not included.
This study was performed on samples taken during
regular clinical work-up procedures and staging after ap-
proval by the Institutional Review Board of the Institute of
Hematology, Clinical Center of Serbia, according to the Hel-
sinki Declaration and good clinical practice policy.
In all patients standard clinical and laboratory data were
collected: age, gender, Ann Arbor stage, extranodal sites,
bulky disease, clinical stage, B symptoms (LDH)
 15. Bulky
disease was defined as a mediastinal mass larger than one
third of the maximum thoracic diameter and/or any node
over 5 cm. The IPI was calculated  according to the five high
risk features: age  >  60 years, performance status  >  2 (PS),
Ann Arbor tumor stage 3 or 4, LDH > 460 IU/µL, and num-
ber of extranodal sites >1 while patients were divided into a
low risk group (0 – 2 factors) and a high-risk group (3 or 4
factors) 
5.
This retrospective analysis was performed on 50 pa-
tients randomly selected from a large group of patients diag-
nosed and treated with CHOP/R-CHOP regimen with or
without adjuvant radiotherapy and/or surgery over a five-
year period.  The response rate was determined according to
standard Cheson criteria 
16.
The 4 µm thick tissue sections were dehydrated and de-
parafinized according to standard procedures and stained
with haematoxylin and eosin, Giemsa and reticulin (Gordon
Sweet), and examined by light microscopy.
For immunohistochemical analysis, pretreatment antgen
retrieval by microwave heating in 10 mM citrate buffer pH 8
was performed according to the manufacturer directions and
current laboratory protocol. Incubation was performed using
the following primary antibodies: bcl-2 (clone 124, Dako,
Denmark) and Ki 67 (clone MIB 1, Dako, Denmark), to-
gether with standard diagnostic panel for DLBC NHL.
Immunoreaction with a standard indirect immunoper-
oxidase technique was developed applying an avidin-biotin
complex method (ABC, LSAB2 kit peroxidase, Dako, Den-
mark) using AEC as chromogen. Sections were counter-
stained with Mayer hematoxylin.
Two hematopathologists reviewed and evaluated all
slides at the time of immunohistochemical analysis. They
confirmed the diagnosis of DLBCL according to criteria out-
lined by the WHO classification. The percentage of tumor
cells with Ki-67+ nuclear staining on 10 different high power
microscopy fields (HPF, 400×) was determined. The inten-
sity of this staining were graded as weak (0-30% Ki-67+),
moderate (31–60% Ki-67+ cells), and strong (>60% Ki-67+
cells). Tumors were considered positive when at least 50% of
tumor cells expressed bcl-2 protein.
The response rates were analyzed according to widely
accepted international Cheson criteria. For the purpose of
statistical analysis, partial remission, non response and pro-
gressive disease were considered as treatment failures. Event
free survival (EFS) was measured from the start of treatment
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of last follow-up. Overall survival (OS) was measured from
the beginning of treatment to the time of last follow-up (cen-
sored patients) or time of death.
For univariate analysis, the χ
2 and Fischer exact tests
were used to assess the association between molecular and
clinical and laboratory variables. Survival analysis was per-
formed by the Kaplan-Meier method. The statistical signifi-
cance of differences in EFS and OS between groups of pa-
tients was estimated by the logrank test. Statistical signifi-
cance of prognostic variables was also evaluated by multi-
variate analysis using Cox proportional hazard model. For
nonparametric variables and analysis of factors influencing
outcome of treatment, nonparametric tests Mann-Whitney U
test and Kruskall-Wallis test were applied.
All tests were two-sided at the threshold of p values =
0.05. Values p  <  0.05 were considered statistically signifi-
cant. All statistical analysis were performed by licensed Sta-
tistical Analysis Software (Stat Soft, Inc. Tulsa USA, 2005.
STATISTICA data analysis software system, version 7.1;
www.statsoft.com) 
16.
Results
Laboratory and clinical features of 50 patients (30
male/20 female) with DLBCL are listed in Table 1. The pa-
tients age ranged from 17–87 years, with the mean age of
50  ±  18.16 years. On presentation, 64% of patients were
classified as being in stage III and stage IV. High IPI was
present in 36% of patients. Initial bulky disease was con-
firmed in 24%, extranodal distribution in 68%, B symptoms
in 76% and LDH > 460 IU/µL in 62% of patients.
After the first line therapy, complete remission (CR)
was achieved in 39 patients (78%), while treatment of 11 pa-
tients failed.  After a 5-year follow-up, 28 (56%) patients
were still in CR, while 22 (44%) patients died.
Statistical analysis of certain clinical variables revealed
that patients with bulky form of the disease had significantly
higher LDH levels (t-test and χ
2 p < 0.05), but there was no
association between bulky disease and other clinical vari-
ables.
Concerning remission rates, we were unable to show
that bulky or extranodal disease, constitutional symptoms or
LDH level bored any relation to CR rates (χ
2 p > 0.05).
According to IPI, the distribution of patients was as
follows: IPI ≤ 1 in 11, IPI 2 in 21 and IPI ≥ 3 in 18 patients,
meaning that low IPI score was present in 32 and high IPI
score in 18 patients. Concerning IPI score values we found
no correlations between low and high IPI and bulky disease.
Univariate survival analysis showed that high IPI had statis-
tically significant negative influence on OS, and also on EFS
(logrank, p < 0.01). Patients with IPI ≥ 3 had significantly
more progressive disease and shorter overall survival (OS5y
not reached, median OS 7 months compared to OS5y of 87%
in patients with low IPI).
Univariate analysis showed that extra nodal disease,
bulky form, and the existence of B symptoms had certain
influence on OS and EFS but these differences were not
statistically significant (log rank, p > 0.05),  whereas  in-
creased LDH level did have a significant effect on overall
survival.
Multivariate analysis revealed that IPI > 3 had an inde-
pendent prognostic impact on survival (p < 0.01)  together
with extranodal distribution and LDH levels (p < 0.05) as a
part of IPI score.
The cell proliferation marker Ki-67 was observed as
nuclear staining in tumor cells and in lymphocytes within the
tumor tissues in all 50 cases. The staining intensity and num-
ber of tumor cells positive to Ki-67 varied from case to case,
ranging from 30% to 95%. None of the patients had more
than 95% Ki-67 positive tumor cells.
Table 1
Clinical data on analyzed patients (n = 50)
Patients' characteristics n %
Gender
     male 30 60
     female 20 40
Constitutional symptoms
     yes
      no
38
12
76
24
Clinical stage
      I, II
    III, IV
18
32
36
64
International Prognostic Index (IPI) score
      low risk
      high risk
32
18
64
36
Bulky disease
      yes
       no
12
38
24
76
Extranodal disease
       yes
       no
34
16
68
32
Lactate dexydrogenase (IU/µL)
> 460
< 460
31
19
62
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Statistical analysis of clinical variables revealed that there
was a correlation between high Ki-67+ and high LDH levels,
but this was not statistically significant (t-test and χ
2 p > 0.05).
Values of Ki-67 positive tumor cells follows the values
of IPI scores, meaning that patients with a high proliferation
rate also had high IPI value (IPI > 3). We found statistically
significant positive correlation between low and high Ki-67+
and IPI scores (χ
2, Mann Whitney U test and Spearman Rank
correlation, p < 0.05)
Thirty of 50 patients (60%) had Ki 67+ in > 60% of tu-
mor cells. In the group with fatal outcome 15 out of 22 pa-
tients had Ki 67+ in > 60% of tumor cells (Figure 1). The
logrank test analysis signified that patients with a high pro-
liferative fraction (Ki-67  >  60%) had a worse overall sur-
vival (OS5y) of 40% compared to those with low prolifera-
tion (Ki-67 < 60%) with OS5y of 80% (p < 0.01) (Figure 2).
In multivariate analysis performed by Cox model we found
that high Ki-67+ (at a threshold of 60% of positive cells) was
marginally significant (p = 0.057).
0
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IPI
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IPI >3 3 15 7 11
IPI <3 17 15 22 10
Ki67 <60% Ki67 >60% bcl-2
<50%
bcl-2
>50%
Fig. 1 – Frequency of Ki-67, bcl-2 and International Progno-
stic Index (IPI) values in diffuse large B cell lymphoma
patients
Antiapoptotic protein bcl-2, was detected as a distinct
cytoplasmic staining pattern of the tumor cells. Immunohis-
tochemical analysis revealed that bcl-2+ was dominantly high
(> 50%) in 21 patients (42% of analyzed cohort) (Figure 1).
Concerning bcl-2 positivity at a threshold level of 50%
of positive labeled cells, we  found the same pattern as was
detected for Ki-67, meaning that patients with high percent-
age of bcl-2+ tumor cells also had high IPI value (IPI > 3)
(Figure 1), and there was statistically significant positive cor-
relation between low and high bcl-2 and IPI scores (χ
2 Mann
Whitney U test and Spearman Rank correlation, p < 0.05).
There was a negative correlation between bcl-2+ and
achievement of CR (66% vs. 86% in patients with bcl-2 high
and low levels respectively, p < 0.05). Patients with low bcl-
2 expression (< 50% of tumor cells) survived significantly
longer (OS5y median time rate 68%) compared to those with
high bcl-2+ (OS5y 37%) (Figure 3).
Multivariate analysis by Cox regression model, re-
vealed that bcl-2 positivity (threshold 50%) had a significant
independent prognostic value concerning overall survival
(p < 0.05). Statistical analysis showed that there was signifi-
cant correlation between high bcl-2 and Ki-67 positivity.
Furthermore these patients had significantly shorter OS
(p < 0.05).
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Fig. 2 – Survival curves of diffuse large B cell lymphoma pa-
tients according to Ki-67 values (Kaplan-Meier)
Overall Survival according to Bcl-2 positivity  
dead   at risk (Kaplan-Meier)
0 1 22 43 64 86 07 2
Time (months)
0.00
0.25
0.50
0.75
1.00
C
u
m
u
l
a
t
i
v
e
 
P
r
o
p
o
r
t
i
o
n
 
S
u
r
v
i
v
i
n
g
 Bcl-2 <50%
 Bcl-2 >50%
Log rank p<0.05
29 pts; 20 at risk
21 pts; 8 at risk
Fig. 3 – Survival curves of diffuse large B cell lymphoma
patients according to bcl-2 values (Kaplan-Meier)
Discussion
Although studies of individual biomarkers have im-
proved our understanding of the pathogenesis of DLBCL,
many studies have yielded conflicting results. Reasons for
these discrepancies include the retrospective nature of most
studies, small patient sample size, lack of uniformity in tech-
nique and failure to control other simultaneous biologic pro-
cesses that may confound outcomes. Importantly, these
markers need to be revalidated in patients who have been
treated with immunochemotherapy 
4.
In the study of Hans et al 
9 the IPI score predicted OS
(p < 0.001) and EFS (p < 0.001) when comparing those with
low (0-2) versus high (3-5) scores. In our study, univariate
survival analysis showed that high IPI had a statistically sig-
nificant negative influence on overall and also on event free
survival time (logrank, p < 0.01). The patients with IPI ≥ 3 had
significantly more progressive disease and shorter overall sur-
vival (OS5y not reached, median OS 7 months compared to
OS5y of 87% in patients with low IPI). Multivariate analysis
revealed that IPI > 3 had an independent prognostic impact on
survival (p  <  0.01) together with extranodal distribution and
LDH levels (p < 0.05). In the study of Colomo et al. 
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also had a high value for predicting OS (p<0.00001). Extrano-
dal disease, bulky disease, and B symptoms had certain influ-
ence on OS and EFS, but these differences were not statisti-
cally significant (logrank, p>0.05). Increased LDH level had
significant effect on overall survival.
Diffuse large B cell lymphoma is heterogenous, and the
expression of bcl-2 is variable 
18.
In most studies, bcl-2 protein expression alone or in
combination with other factors (e.g. high IPI) is regarded as
evidence of both t (14;18) and an aggressive clinical course,
the OS and disease-free survival curves being significantly
worse than in bcl-2- cases (19–22). In the study of Colomo et
al. 
17 bcl-2 expression was included in the Cox model along
with the IPI (low risk vs low/intermediate-risk vs
high/intermediate-risk vs high-risk). Bcl-2 maintained a trend
of independent prognostic value, although the IPI remained
most significant variable.
Concerning bcl-2 positivity at the threshold level of
50% of positive tumor cells, we have found that patients with
high percentage of bcl-2+ tumor cells also had high IPI value
(IPI > 3), and there was statistically significant positive cor-
relation between low and high bcl-2 and IPI scores (χ
2, Mann
Whitney U test and Spearman Rank correlation, p < 0.05).
Furthermore, there was a clear difference between bcl-2+
and the achievement of CR (66% vs 86% in patients with
bcl-2 high and low levels respectively, p < 0.05). Multivari-
ate analysis by Cox regression model revealed that bcl-2
positivity (threshold 50%) had a significant independent
prognostic value concerning OS (p < 0.05).
However, multiple studies have looked at the expres-
sion of bcl-2 using immunostains, and most have found no
difference in OS (23–25).
 A critical look at the various results during the last 10
years shows considerable variation. Although a predictive
value for DFS is reported in most series, the predictive value
of bcl-2 positivity for OS is not reliably consistent among
those reports. Although some series may lack the statistical
power to detect survival difference, variations in scoring and
interpreting bcl-2 staining are likely to account for such dis-
crepancies 
26.
The prognostic significance of Ki-67 expression in
DLBCL is controversial 
6. Tumors with low Ki-67 index may
exibit resistance to chemotherapy, given that the majority of
the malignant cells are in G0/G1 and thus are resistant to cycle
specific cytotoxic chemotherapy. Furthermore, G0/G1 arrested
cells have time to repair DNA damage induced by the chemo-
therapy and thus survive 
6. The proliferative fraction in
DLBCL as detected by Ki-67 staining is usually high (> 40%)
and may be greater than 90% in some cases 
27.
Miller et al. 
26 analyzed the prognostic significance of
Ki-67 staining in 60 representative DLBCL patients from the
Intergroup 0067 study that compared four different antracy-
cline-based  regimens, and found that the 3-year OS was sig-
nificantly shorter in patients with Ki-67 nuclear expression in
80% or more malignant cells. In a subsequent study on 105
DLBCL patients, the same authors demonstrated that high
proliferative activity, defined in this study as nuclear Ki-67
expression in greater than 60% of malignant cells, was a
strong predictor of poor survival (logrank, p = 0.003,) 
27. The
Nordic Lymphoma Group Study defined low expresion of
Ki-67 as less than 60% of tumor cells, and found that expres-
sion of Ki-67 was not associated with significant differences
in a 5-year OS 
28.
We found that values of Ki-67 positive tumor cells fol-
lows the values of IPI scores, meaning that patients with high
proliferation rate also had high IPI value (IPI > 3). There was
a statistically significant positive correlation between low
and high Ki-67+ and IPI scores (χ
2, Mann Whitney U test
and Spearman Rank correlation, p < 0.05). The logrank test
analysis signified that patients with a high proliferative frac-
tion (Ki67 > 60%) had worse overall survival (OS5y) of 40%
compared to those with low proliferation (Ki67 < 60%) with
OS5y of 80% (p < 0.01) (Figure 2). In multivariate analysis
performed by Cox model we found that high Ki-67+ (at a
threshold of 60% of positive cells) was marginally signifi-
cant  (p = 0.057).
Conclusion
We found that a high percentage of bcl-2 and Ki-67
positive tumor cells was associated with worse prognosis.
Furthermore there was positive correlation between these
molecular parameters and high IPI score.
Taken together, biological factors in combination with
clinical models such as IPI, might become an integral part of
our daily practice in finding a way to a more individualized
or patient-tailored practice in oncology.
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